225 related articles for article (PubMed ID: 23041228)
1. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.
Blanco-Aparicio C; Carnero A
Biochem Pharmacol; 2013 Mar; 85(5):629-643. PubMed ID: 23041228
[TBL] [Abstract][Full Text] [Related]
2. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
[TBL] [Abstract][Full Text] [Related]
3. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
4. Expression and function of PIM kinases in osteosarcoma.
Mou S; Wang G; Ding D; Yu D; Pei Y; Teng S; Fu Q
Int J Oncol; 2016 Nov; 49(5):2116-2126. PubMed ID: 27826617
[TBL] [Abstract][Full Text] [Related]
5. PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
Xu J; Zhang T; Wang T; You L; Zhao Y
Future Oncol; 2014 Apr; 10(5):865-76. PubMed ID: 24799066
[TBL] [Abstract][Full Text] [Related]
6. PIM kinase (and Akt) biology and signaling in tumors.
Warfel NA; Kraft AS
Pharmacol Ther; 2015 Jul; 151():41-9. PubMed ID: 25749412
[TBL] [Abstract][Full Text] [Related]
7. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
8. The PIM kinases in hematological cancers.
Alvarado Y; Giles FJ; Swords RT
Expert Rev Hematol; 2012 Feb; 5(1):81-96. PubMed ID: 22272708
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
10. The role of PIM1/PIM2 kinases in tumors of the male reproductive system.
Jiménez-García MP; Lucena-Cacace A; Robles-Frías MJ; Narlik-Grassow M; Blanco-Aparicio C; Carnero A
Sci Rep; 2016 Nov; 6():38079. PubMed ID: 27901106
[TBL] [Abstract][Full Text] [Related]
11. PIM kinases as therapeutic targets against advanced melanoma.
Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A
Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973
[TBL] [Abstract][Full Text] [Related]
12. The PIM family of serine/threonine kinases in cancer.
Narlik-Grassow M; Blanco-Aparicio C; Carnero A
Med Res Rev; 2014 Jan; 34(1):136-59. PubMed ID: 23576269
[TBL] [Abstract][Full Text] [Related]
13. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
[TBL] [Abstract][Full Text] [Related]
14. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
[TBL] [Abstract][Full Text] [Related]
15. Targeting Pim kinases for cancer treatment: opportunities and challenges.
Le BT; Kumarasiri M; Adams JR; Yu M; Milne R; Sykes MJ; Wang S
Future Med Chem; 2015; 7(1):35-53. PubMed ID: 25582332
[TBL] [Abstract][Full Text] [Related]
16. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
Liang C; Li YY
Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
[TBL] [Abstract][Full Text] [Related]
17. The essential role of PIM kinases in sarcoma growth and bone invasion.
Narlik-Grassow M; Blanco-Aparicio C; Cecilia Y; Peregrina S; Garcia-Serelde B; Muñoz-Galvan S; Cañamero M; Carnero A
Carcinogenesis; 2012 Aug; 33(8):1479-86. PubMed ID: 22623646
[TBL] [Abstract][Full Text] [Related]
18. The Pim kinases: new targets for drug development.
Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F
Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Pim kinases in multiple myeloma.
Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
Yang Q; Chen LS; Gandhi V
Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
